Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (vibegron) 75 mg at 20 Apr 13, 2022 12:02PM
Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902 Mar 7, 2022 11:56AM
Urovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Symptom Reduction for Overactive Bladder Patients Treated with GEMTESA® Dec 20, 2021 12:11PM
Urovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients Nov 8, 2021 08:00AM
Urovant Sciences (UROV) Announces Co-Promotion Agreement for Vibegron with Sunovion Pharmaceuticals Oct 7, 2020 08:09AM


Oct 7, 2020 08:00AM Urovant Sciences Announces Co-Promotion Agreement for Vibegron with Sunovion Pharmaceuticals
Jun 19, 2020 09:24PM Sumitovant Biopharma Announces Urovant Sciences Collaboration with Sunovion Pharmaceuticals
Jun 18, 2020 08:03AM Urovant Sciences (UROV) Enters Collaboration with Sunovion Pharmaceuticals
Jun 18, 2020 08:00AM Urovant Sciences Announces Collaboration with Sunovion Pharmaceuticals